

Title

The distinct clinical features and prognosis of the CD10⁺MUM1⁺ and CD10⁻Bcl6⁻MUM1⁻ diffuse large B-cell lymphoma

Name of authors

Ting-Xun Lu, Yi Miao, Jia-Zhu Wu, Qi-Xing Gong, Jin-Hua Liang, Zhen Wang, Li Wang, Lei Fan, Dong Hua, Yao-Yu Chen, Wei Xu, Zhi-Hong Zhang, Jian-Yong Li

Table S1. The clinical characteristics between the total cohort and the chemoimmunotherapy cohort

Variables	Total cohort no. (%)	R-CHOP-like cohort no. (%)	<i>P</i> value
Age	601	306	
> 60y	259 (43.1)	133 (43.5)	0.915
≤ 60y	342 (56.7)	173 (56.5)	
Sex	601	306	
Male	345 (57.4)	180 (58.8)	0.682
Female	256 (42.6)	126 (41.2)	
LDH	600	306	
Over ULN	302 (50.3)	138 (45.0)	0.136
Normal	298 (49.7)	168 (55.0)	
Stage	600	306	
I/II	226 (37.7)	118 (38.6)	0.793
III/IV	374 (62.3)	188 (61.4)	
ECOG PS	597	306	
0-1	484 (81.1)	244 (79.7)	0.631
2-4	113 (18.9)	62 (20.3)	
ESI	600	306	
0-1	460 (76.7)	224 (73.2)	0.252
> 1	140 (23.3)	82 (26.8)	
IPI	597	306	
0-2	398 (66.7)	201 (65.7)	0.768
> 2	199 (33.3)	105 (34.3)	
B symptom	597	306	
Positive	218 (36.5)	103 (33.7)	0.396
Negative	379 (63.5)	203 (66.3)	

Abbreviations: LDH: serum lactate dehydrogenase; ULN: upper limit of normal; ECOG PS: Eastern Cooperative Oncology Group performance status; ESI: more than one extranodal sites involvement; IPI: International prognostic index.

Table S2. The differences of clinical features of DP or TN group between the total cohort and the chemoimmunotherapy cohort

Variables	DP			TN		
	Total cohort	R-CHOP-like cohort	<i>P</i> value	Total cohort	R-CHOP-like cohort	<i>P</i> value
	no.(%)	no.(%)		no.(%)	no.(%)	
Age	80	49		53	30	
> 60y	36 (45)	22 (44.9)	0.991	23 (43.4)	13 (43.3)	0.996
≤ 60y	44 (55)	27 (55.1)		30 (56.6)	17 (56.7)	
Sex	80	49		53	30	
Male	42 (52.5)	25 (51.0)	0.870	29 (54.7)	17 (56.7)	0.864
Female	38 (47.5)	24 (49.0)		24 (45.3)	13 (43.3)	
LDH	79	49		53	30	
Over ULN	30 (38.0)	16 (32.7)	0.542	25 (47.2)	13 (43.3)	0.736
Normal	49 (62.0)	33 (67.3)		28 (52.8)	17 (56.7)	
Stage	79	49		53	30	
I/II	39 (49.4)	25 (51.0)	0.856	22 (44.0)	8 (26.7)	0.176
III/IV	40 (50.6)	24 (49.0)		31 (56.0)	22 (73.3)	
ECOG PS	78	49		53	30	

	0-1	66 (84.6)	40 (81.6)		46 (86.8)	25 (83.3)	
	2-4	12 (15.4)	9 (18.4)	0.660	7 (13.2)	5 (16.7)	0.749
ESI		79	49		53	30	
	0-1	62 (78.5)	38 (77.6)		43(81.1)	22 (73.3)	
	> 1	17 (21.5)	11 (22.4)	0.902	10(18.9)	8 (26.6)	0.408
IPI		78	49		53	30	
	0-2	59 (75.6)	37 (75.5)		41 (77.4)	20 (66.7)	
	> 2	19 (24.4)	12 (24.5)	0.987	12 (22.6)	10 (33.3)	0.289
B symptom		78	49		53	30	
	Positive	18 (23.1)	11 (22.4)		17 (32.1)	12 (40.0)	
	Negative	60 (76.9)	38 (77.6)	0.935	36 (67.9)	18 (60.0)	0.467

Abbreviations: GCB: germinal center B-cell; DP: double positive (CD10⁺MUM1⁺); LDH: serum lactate dehydrogenase; ULN: upper limit of normal; ECOG PS: Eastern Cooperative Oncology Group performance status; ESI: more than one extranodal sites involvement; IPI: International prognostic inde

Figure Legends

Figure S1. The immunohistochemical staining of the antibodies used in this study.

(A) CD10 positive. (B) CD10 negative. (C) MUM1 positive. (D) MUM1 negative. (E) Bcl6 positive. (F) Bcl6 negative. (G) Myc positive. (H) Myc negative. (I) Bcl2 positive. (J) Bcl2 negative.

Figure S2. FISH results of each probe

(A) *MYC*-R⁺. (B) *MYC*-R⁻. (C) *BCL2*-R⁺. (D) *BCL2*-R⁻. (E) *BCL6*-R⁺. (F) *BCL6*-R⁻.

Abbreviations: R: rearrangement; ⁺: positive; ⁻: negative.



